Dr. Molly Davis, MD

I graduated with distinction from Stanford University with a B.S. in Human Biology. I received my M.D. from the University of Washington School of Medicine in 2001, followed by a general psychiatry residency and geriatric psychiatry fellowship at Oregon Health & Science University (OHSU), where I served as chief resident in my final year. I am board-certified in both general and geriatric psychiatry.

After completing my training, I joined the faculty at OHSU as a geriatric psychiatrist. My clinical focus included diagnosis and management of treatment-resistant mood disorders with electroconvulsive therapy (ECT), assessment and treatment of major neurocognitive disorders (dementia), and diagnosis and treatment of movement disorders.  Throughout my career, I have focused on assessment and treatment of complex neuropsychiatric conditions. I have additional training in neurology and movement disorders.  I have worked across a range of inpatient and outpatient psychiatric settings.  Since 2014, my focus has been on using deep transcranial magnetic stimulation (dTMS) to treat treatment-resistant mental illness.

I co-founded Clear Path Psychiatry with Dr. Eliza Brink, PMHNP, DNP. Clear Path is an innovative interventional psychiatry practice in Seattle, Washington. We offer deep rTMS to treat treatment-resistant depression and obsessive-compulsive disorder, using the BrainsWay H1 and H7 coils. We also provide Spravato (intranasal esketamine) for patients suffering from treatment-resistant depression or depression with suicidal thoughts. We offer both once daily TMS through insurance, in addition to off-label (private pay) accelerated TMS protocols.

In 2018, I immersed myself in studying psychedelic medicine. I am trained through the Multidisciplinary Association for Psychedelic Studies (MAPS) to offer MDMA-assisted therapy for individuals with treatment-resistant PTSD pending FDA approval. I completed a year-long fellowship through the Integrative Psychiatry Institute in psychedelic-assisted therapy and am eager to offer psychedelic medicines as they gain FDA approval.

My personal experience with life-threatening illness has shaped my approach as a psychiatrist. I was diagnosed with triple-negative breast cancer in 2018, followed by therapy-related acute myeloid leukemia in 2020, requiring a stem cell transplant. My experience navigating life as a patient gave me firsthand insight into the challenges faced by individuals with life-threatening illnesses and those confronting mortality.  I know the frustrations of navigating the medical system while sick. I am passionate about working with people who live with life-threatening and chronic illnesses. I believe that psychedelic medicine, in particular, can help individuals find meaning, hope, and joy in their lives, even when facing grief, loss, chronic illness and mortality.

I am currently the principal investigator for several clinical trials, including two studies investigating accelerated TMS (multiple TMS sessions per day) and a trial investigating a psychedelic medicine trial for postpartum depression.  I am passionate about research that will advance the field of interventional psychiatry and improve access to these treatments.